Navigation Links
Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
Date:8/29/2013

KANSAS CITY, Kan., Aug. 29, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it will host a Pet Therapeutics Primer and Product Update Event, to be held September 11, 2013, at the Four Seasons Hotel in Boston. 

The purpose of the event is to comprehensively lay out the pet therapeutics regulatory framework and to provide a detailed program-by-program update on Aratana's current pet therapeutic development programs.Event:Pet Therapeutics Primer & Product UpdateDate: Wednesday, September 11, 2013 Time: 6:00 – 7:30 p.m. (Eastern Time) Location:Parris Room; Four Seasons Hotel BostonThe event will be webcast live beginning with the company presentations at 6:30 p.m. Eastern Time, and will then be made available as an archive on the Aratana Therapeutics website at aratana.investorroom.com.

Program Agenda:
Dr. Steven St. Peter, President and Chief Executive Officer of Aratana Therapeutics, will provide a brief introduction to the Company and its pipeline of pet therapeutic product candidates.  He also will discuss Aratana's licensing and partnership strategy for expanding its development pipeline.

Dr. Linda Rhodes, Aratana's Chief Scientific Officer, will provide an overview of the regulatory framework at the FDA's Center for Veterinary Medicine; specifically, the three concurrent regulatory work-streams: safety, efficacy and manufacturing.  Dr. Rhodes also will discuss the mechanics of filing an administrative New Animal Drug Application (NADA) and the subsequent notification of approval. 

Dr. Ernst Heinen, Aratana's Head of Drug Development and Evaluation, will provide an in-depth development update for each of Aratana's current product candidates, each of which is being developed concurrently for both cats and dogs.  These include AT-001, the Company's EP4 antagonist for the treatment of pain; AT-002, its ghrelin agonist for treating inappetence; and AT-003, Aratana's liposomal bupivacaine injection for treating post-operative pain.

There will be an opportunity for Q&A after each session, during which Dr. Marie-Paul Lachaud, Aratana's Head of Drug Development in Europe; Tammy Newbold, Aratana's Vice President of Chemistry, Manufacturing and Controls; and Don Stitzenberg, Aratana's Vice President of Manufacturing, will also be available.

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
6. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
7. Aratana to Participate in Leerink Swanns November Management Access Days
8. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
9. Echo Therapeutics Announces Management Changes
10. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
11. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017   Alberty   ... Batavia, NY has announced a significant shift ... and wellness programs to servicing local Veteran Affairs Centers ... budgets and an increased need to secure cost effective ... to source locally for their goods & services. ...
(Date:2/19/2017)... February 18, 2017 Marapharm (OTCQB: ... purchase a Medical Delivery Service with the specific and ... between qualified patients and caregivers. The delivery service is ... in the Coachella Valley, California . ... Angeles area to the West, population 19,000,000. ...
(Date:2/17/2017)... , February 17, 2017 Cryoablation, Electrical, Endometrial ... The global ablation technologies market is expected to grow at ... 2022-2027. The market is expected to grow at a CAGR of ... in 2016, and $9.05bn in 2026. ... How this report will benefit you Read ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 2017 , ... Today, Illuma Care Connections, a new care ... 2017 Annual HIMSS Conference & Exhibition in Orlando, Florida, February 19-23, ... eye care into mainstream healthcare delivery is powered by Secure Exchange Solutions ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/18/2017)... ... 2017 , ... Focused start-ups, not traditional health care organizations, ... the recent NEJM Catalyst Insights Report on the New Marketplace. , NEJM ... a qualified group of U.S. executives, clinical leaders, and clinicians at organizations directly ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 features ... ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great for ... and choose from hand-crafted trend-setting designs with smooth animations that will add stylistic ...
(Date:2/17/2017)... Diego, CA (PRWEB) , ... February 17, 2017 ... ... initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively impact ... , “The Board of Trustees has long considered it our duty to seriously ...
Breaking Medicine News(10 mins):